Payment & Shipping Terms:
|Usage:||Breast Cancer Treatment|
healthy anabolic steroids,
CAS 566 48 3 Estrogen Steroid Raws Formestane For Breast Cancer Treatment Lentaron
Formestane/Lentaron Basic Info:
CAS No: 566-48-3
Einecs No: 219-112-8
Appearance: white crystalline powder
|Production Bath||20190312||Production Date||2019/3/12|
|Specification||Enterprise Standard||Shelf life||2 Years|
|Result For Analysis|
|Appearance||White or Almost White Crystalline Powder||Conforms|
|Loss On Drying||0.50%||0.32%|
|Specific Rotation||+172~+182°||+174.5 ~+181°|
|Assay||not less than 97%||99.80%|
|Conclusion||Conforms Specifications of Enterprise Standard.|
Formestane Is the second generation of irreversible steroid aromatase inhibitors. It inhibits the aromatase responsible for converting androgen into estrogen, thereby preventing estrogen production. Breast cancer may be estrogen-sensitive or insensitive. Most breast cancers are estrogen-sensitive. Estrogen-sensitive breast cancer cells are dependent on estrogenic activity. Therefore, removal of estrogen from the body can become an effective treatment for hormone-sensitive breast cancer.
Formestane is dedicated to the treatment of postmenopausal women. Unlike premenopausal women who produce the most estrogen in the ovaries, postmenopausal women produce most estrogens in peripheral tissues with the help of aromatases. Methanesulfonamide aromatase inhibitors can help reduce the production of estrogen by blocking aromatase (ie, attached to mammary gland tissue) in peripheral tissues to treat hormone-sensitive breast cancer.
Formestane is Also known as lentaron, is an anti-cancer drug, mainly used for the treatment of advanced breast cancer in postmenopausal women, also effective for prostate cancer.
Methanesulfonic acid is a androstenedione derivative, an aromatic enzyme inhibitor with amino hydroxyethyl amide, is a hormone antineoplastic agent. Under physiological conditions, it may competitively inhibit the synthesis of enzymes, resulting in reduced estrogen biosynthesis in the tissue, and then it works in cancer. When tumor tissue growth depends on the presence of estrogen, it is necessary to eliminate tumor estrogen-mediated growth stimuli in order to inhibit tumor growth.
The product is more selective than amino isoflavones, and its activity is amino-hydroxyethylamine 100 to 1000 times, does not inhibit the synthesis of adrenal hormones, without the need to add cortisone and so on. The in vitro inhibition of the product's aromatase is 60 times stronger than that of aminosuccinimide.
When it is used alone, when it is combined with goserelin (gonadotropin-releasing hormone agonist), the drug does not significantly reduce premenopausal estrogen levels in women's blood, and estrogen inhibition in premenopausal women The effect is greater than that of goserelin alone using methanesulfonic acid with other aromatase inhibitors without cross resistance, which does not have side effects of aminoglucan.
After oral administration, it is rapidly absorbed by the gastrointestinal tract, the plasma concentration of the peak time of 1 ~ 1.5 hours, but the individual peak concentration difference; intramuscular injection, can be accumulated in the injection site and slowly absorbed. It performs a biphasic elimination process, the initial elimination half-life of 2 to 4 days, the terminal elimination half-life of 5 to 10 days. After oral administration mainly in the liver metabolism, uridine excretion of glycoside metabolites in the form of existence.
Formestane is a second generation, irreversible, steroidal aromatase inhibitor. It inhibits the aromatase enzyme responsible for converting androgens to estrogens, thereby preventing estrogen production. Breast cancer may be estrogen sensitive or insensitive. A majority of breast cancers are estrogen sensitive. Estrogen sensitive breast cancer cells depend on estrogen for viability.
Thus removal of estrogen from the body can be an effective treatment for hormone sensitive breast cancers. Formestane has been targeted specifically for the treatment of postmenopausal women. Unlike premenopausal women who produce most estrogen in the ovaries, postmenopausal women produce most estrogen in peripheral tissues with the help of the aromatase enzyme. Formestane, an aromatase inhibitor, can thus help to decrease the local production of estrogen by blocking the aromatase enzyme in peripheral tissues (ie. Adispose tissue of the breast) to treat hormone sensitive breast cancer.
The Product List
|Product Name||CAS No.|
|4-Chlorotestosterone acetate (Clostebol acetate)||855-19-6|
|Trenbolone Acetate (Finaplix H/Revalor-H)||10161-34-9|
|Trenbolone Hexahydrobenzyl Carbonate||23454-33-3|
|Boldenone Undecylenate (Equipoise)||13103-34-9|
|Superdrol Powder (Methyl-drostanolone)||3381-88-2|
|Methandrostenolone (Dianabol, methandienone)||72-63-9|
|Tamoxifen Citrate (Nolvadex)||54965-24-1|
Contact Person: tommy